Oxford BioDynamics launches its Checkpoint Inhibitor response test in the US
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
100% efficacy against severe Covid-19 disease and hospitalizations
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The facility will manufacture its Herceptin biosimilar, Tuznue
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Subscribe To Our Newsletter & Stay Updated